Schedule 13D ownership disclosure
Spero Therapeutics Inc
Common Stock, Par Value $0.001 · CUSIP: 84833T103
Event date: 2025-03-27
- Filing-level shares
- 9,190,606.00
- Percent of class
- 16.4%
- GSK PLCReported CIK 0001131399
Shares: 9,190,606.00 · Class: 16.4%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001999371-25-003391
- Form type
- SCHEDULE 13D/A
- Filer
- GSK plc
- CIK
- CIK 1131399
- Filed
- Mar 28, 2025
- Reporting period
- Mar 27, 2025
- Description
- Schedule 13D beneficial ownership